Weight-loss drug developer Metsera reveals wider loss in US IPO submitting

(Reuters) – Weight-loss drug developer Metsera, backed by ARCH Enterprise Companions, revealed a wider loss in its paperwork for a U.S. preliminary public providing on Friday.

The phrases of the IPO weren’t disclosed within the submitting.

Robust fairness markets, falling rates of interest and hopes of a friendlier regulatory atmosphere below the incoming Trump administration have given a push to corporations seeking to record their shares.

Metsera, based in 2022 by enterprise capital agency ARCH Enterprise and funding agency Inhabitants Well being Companions, revealed a internet lack of $156.26 million within the first 9 months of 2024, in comparison with a lack of $34.18 million in the identical interval in 2023.

Metsera intends to record its shares on the Nasdaq International Market below the ticker image “MTSR”.

BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities and Cantor are the underwriters for the providing.